Humana specialty drug prior authorization — care coordinator playbook

End-to-end PA workflow

Humana specialty drug prior authorization is a four-phase workflow for the PCC: line-of-business and benefit-channel verification (the make-or-break fork between Part B and Part D), hub program enrollment or charitable-foundation grant routing for Medicare patients, PA submission through the correct portal and criteria set, and reauth tracking. Where billers most often trip is calling the wrong channel (submitting a Part B drug through CenterWell’s Part D pathway, or a self-administered Part D drug through HumanaProvider.com PAAN), missing the CMS Step Therapy attestation for MA Part B biosimilar-eligible reference products, missing CED registry enrollment for amyloid Alzheimer’s mAbs, and treating manufacturer copay assistance as available to MA patients when it is categorically prohibited.

Where the Humana workflow breaks

Four failure patterns drive most stalled Humana specialty PAs:

1. Part B vs Part D miscall. A self-administered SC injectable submitted as Part B through HumanaProvider.com PAAN, or a clinician-administered IV submitted to CenterWell as Part D — both get bounced into the wrong queue with the wrong criteria set, and the rejection is rarely instantaneous. Use the dispensing pattern (does the patient inject at home, or does a clinician administer in clinic?) as the unambiguous test.
2. Missing CMS Step Therapy documentation on MA Part B. Humana enforces CMS-permitted MA Part B step therapy on biosimilar-eligible reference products (Avastin, Herceptin, Remicade, Rituxan, Neulasta, Humira where applicable to MA Part D). PAs submitted without step-through documentation auto-pend pending RFI.
3. Missing CED registry enrollment for amyloid Alzheimer’s mAbs. Leqembi and Kisunla require CMS-approved CED registry enrollment (ALZ-NET is the dominant registry) with per-patient data submission. PAs submitted without registry evidence are denied under the CMS NCD requirement.
4. Manufacturer copay assistance routing for MA patients. Federal anti-kickback statute prohibits manufacturer copay assistance for Medicare beneficiaries. Foundation grants (charitable 501(c)(3)) are the supplemental funding pathway; misrouting to manufacturer assistance triggers compliance issues and delays the patient’s access.

Provider portals

Humana’s provider-facing ecosystem is anchored by HumanaProvider.com (the main provider portal) with Availity Essentials as the cross-payer alternative most practices already have credentialed. CenterWell Specialty Pharmacy operates its own provider-facing referral portal for Part D specialty referrals. TRICARE workflows are entirely separate and live on Humana Military’s portal.

PA fax numbers by drug class

The most reliable workflow on Humana submissions is to pull the current drug-specific PA form fresh from HumanaProvider.com (or the CenterWell provider portal for Part D specialty) each time, since the form itself prints the current submission fax at the top and reflects the most recent CMS Step Therapy and CED registry requirements.

Peer-to-peer (P2P) review requests

Peer-to-peer review is Humana’s pre-appeal pathway for the prescribing physician to discuss a denied or pended PA with the reviewing medical director. For MA Part B and Part D drug denials, P2P is usually faster than filing a Plan Reconsideration and can resolve denials based on missing or misinterpreted clinical context. CMS-regulated TATs apply at the Plan Reconsideration level if P2P does not resolve.

P2P request workflow

1. Read the denial letter carefully. The denial notice lists the P2P scheduling phone number and the window in which P2P can be requested. Identify whether the denial is MA Part B, MA Part D, commercial (legacy), or TRICARE — each routes through a different P2P queue with a different medical director pool.
2. Call the P2P scheduling line. Have the member ID, denial reference number, prescribing physician name and direct callback, and physician’s available windows over the next 3 business days. Humana typically schedules a 15-minute call window within 24-72 hours.
3. Confirm in writing. Document the scheduled time, the queue (MA Part B / MA Part D / commercial / TRICARE), the reviewer specialty if disclosed, and the reference number.
4. Prep the prescriber. Hand off the documentation packet (below) at least 4 hours before the call so the prescriber walks in cold-prepared, not improvising.
5. Document the call. Capture who from Humana participated (name and credential), the decision (approve, uphold, downgrade), reference number, and any commitments around resubmission with additional information. Decisions made on the call should be reflected in writing within 24-72 hours.

Pre-call documentation checklist

• The original PA submission package.
• The denial letter with the stated reason and the cited Humana medical coverage policy reference (or CMS Step Therapy / NCD reference).
• The most recent clinical note (within 30-60 days) supporting the indication.
• Prior therapy timeline with dates, doses, durations, and documented response or intolerance — especially for biosimilar step-through and CMS Step Therapy compliance.
• Compendia citation for off-label use (NCCN Category 1 or 2A, DrugDex Cat I or IIa, AHFS).
• Laboratory or imaging supporting the indication (e.g., HER2 IHC/FISH for HER2-targeted therapy, EGFR mutation for EGFR-targeted therapy, amyloid PET or CSF biomarker for Alzheimer’s mAb).
• For amyloid Alzheimer’s mAbs (Leqembi, Kisunla): documentation of CED registry (ALZ-NET) enrollment, baseline MRI for ARIA monitoring, and APOE genotype documentation.
• For TRICARE: TRICARE-specific benefit and PA documentation; TRICARE rules do not always align with MA criteria.

Suggested prescriber talking points

Site-of-care policy

Humana’s site-of-care steerage posture is materially less aggressive than UHC’s in the commercial book (a function of how small Humana’s commercial book is post-2024 exit) and CMS-driven for MA Part B. The dominant site-of-care framework on Humana MA Part B drugs is the relevant CMS Local Coverage Determination (LCD) and National Coverage Determination (NCD), plus Humana medical coverage policies where CMS permits payer-specific overlay. Office-based infusion (POS 11) is generally preferred over HOPD (POS 22) on cost grounds for self-funded and capitated arrangements, but Humana has not built a UHC-style dedicated site-of-service PA gate that runs as a parallel review on the drug PA submission.

Site-of-care exception workflow

When HOPD administration is medically necessary on a Humana MA Part B claim and the relevant LCD or Humana medical policy steers to office-based or home infusion, document the medical necessity for HOPD in the clinical note and on the PA submission. The exception submission should include: the clinical reason HOPD is necessary (prior Grade 3+ infusion reaction with intervention, hemodynamic instability, concurrent comorbidity requiring HOPD-level monitoring, complex pediatric or geriatric situation), the failed or contraindicated alternative sites, the prescribing physician’s attestation, and the planned administration protocol. Submit through HumanaProvider.com PAAN with the drug PA. Site-of-care exceptions are typically decided within the same TAT as the drug PA, not as a parallel separate review.

Biosimilar mandate policy

Humana’s biosimilar posture in 2026 is split by benefit channel and shaped by CMS rules on the MA side. On MA Part B, Humana enforces CMS-permitted step therapy on biosimilar-eligible reference products: documented prior trial of a preferred biosimilar (or documented intolerance / contraindication) is the practical requirement for approval of the reference product. On MA Part D, the formulary tier structure is the dominant lever — biosimilars are typically placed on a preferred specialty tier with lower copay than the reference product. Humana’s overall biosimilar enforcement is less aggressive than UHC’s commercial mandate in the sense that there is no UHC-style mandatory substitution policy for continuing patients on commercial, but the CMS Step Therapy framework on MA Part B is real and increasingly comprehensive.

Biosimilar exception criteria

Humana will consider an exception to step therapy on biosimilar-eligible reference products when the prescriber documents one of: a prior trial of the preferred biosimilar with documented intolerance or AE; documented immunogenicity (anti-drug antibody formation) on the biosimilar; loss of clinical response on the biosimilar after switch; or a clinical situation where switching from reference to biosimilar carries documented risk (rare immunogenicity concerns in stable maintenance patients with specific clinical histories). For MA Part B, the exception submission should explicitly address CMS Step Therapy criteria. For MA Part D, the formulary-exception form is the documented pathway and requires the prescriber attestation language specified by CMS Part D regulations.

Specialty pharmacy network

Humana’s in-network specialty pharmacy ecosystem is anchored by CenterWell Specialty Pharmacy (formerly Humana Specialty Pharmacy / Humana Pharmacy, rebranded 2022-2024). CenterWell handles both mail-order and specialty Rx for the bulk of Humana’s Part D specialty volume across MA-PD and stand-alone PDP plans. A limited set of additional specialty pharmacies remain in-network for specific drug classes, specific manufacturer-mandated dispensing arrangements (REMS-restricted distribution), and limited-distribution oncology drugs that ship only through the manufacturer’s designated specialty pharmacy network.

White-bagging vs brown-bagging vs buy-and-bill

Buy-and-bill remains the default for Humana MA Part B medical-benefit drugs — the practice purchases the drug, administers it, and bills the medical benefit at the CMS ASP+6% Medicare rate with Humana’s MA wrap. JW/JZ waste reporting, JG/TB 340B reporting (where applicable), and KX LCD attestation apply on Part B claims the same way they do on Original Medicare claims.

White-bagging (specialty pharmacy dispenses and ships to the site of care for administration) is used selectively for designated Humana drugs where the medical-pharmacy boundary crosses (e.g., select specialty drugs that bridge Part B and Part D contexts). Humana’s white-bagging posture is less aggressive than UHC’s commercial program, in part because the MA Part B framework is largely buy-and-bill by CMS design.

Brown-bagging (patient brings drug from a specialty pharmacy to the administration site) is generally not permitted by Humana for parenteral specialty drugs due to chain-of-custody and stability concerns.

For Part D self-administered specialty drugs, the dispensing flows through CenterWell or another in-network Part D specialty pharmacy and ships directly to the patient at home.

Step therapy requirements

Humana’s step therapy posture in 2026 is dominated by the CMS-permitted MA Part B step therapy framework on the medical-benefit side, plus standard Part D formulary-tier-driven step therapy on the pharmacy side. Step-through documentation is most consistently required across the major specialty therapeutic areas:

Step therapy exception language

Humana MA Part B step therapy exceptions follow the CMS-permitted framework: the prescriber must document intolerance (with specific AE description and date), contraindication (with ICD-10 code or clinical reason), failure (with specific clinical metric and treatment duration), or prior payer step-through grandfathering (the patient completed the step-through under a prior Medicare Advantage plan or other coverage and continued response on the requested agent). MA Part D exceptions follow standard CMS Part D coverage-determination exception language and require the prescriber-attestation form for non-formulary, tier exception, and quantity-limit exception requests.

Common denials and how to fix them

Appeals process

Humana MA appeals follow the CMS-regulated MA appeals structure with CMS-mandated TATs at each level. For Part B and Part C denials: Plan Reconsideration (Level 1 internal redetermination by Humana — TAT 30 calendar days standard pre-service, 72 hours expedited), Independent Review Entity (Level 2 — C2C Innovative Solutions handles Part C / Part B IRE), Administrative Law Judge hearing, Medicare Appeals Council review, and Federal Court review. For Part D coverage determinations: Coverage Determination Redetermination (Level 1 — TAT 7 calendar days standard pre-service Part D, 72 hours expedited), IRE (Level 2 — Maximus Federal Services handles Part D IRE), ALJ, MAC, Federal Court. The Part D Coverage Determination process also offers an expedited appeal pathway for situations where standard TAT would seriously jeopardize the enrollee’s health. Always read the denial notice for the level-1 deadline — it varies by Part B vs Part D and standard vs expedited, and missing the window forfeits the appeal right at that level.

Reauthorization intervals

Reauth workflow

Calendar the reauth date 45-60 days before expiration. Refresh the clinical packet with: the most recent clinical note (within 30-60 days), current labs or imaging required by the drug class, current dose record showing on-label compliance, and any new diagnosis information. For amyloid Alzheimer’s mAbs, maintain CED registry data submission on the registry’s schedule — gaps in registry data can itself become a coverage event. Submit the reauth through the same channel as the original PA (MA Part B via HumanaProvider.com / Availity; MA Part D via CenterWell or CoverMyMeds). If reauth is submitted late and approval lapses, document any therapy continuation gap and prepare a justification for continuation pending re-approval; Humana’s grace policy for in-progress reauth varies by line of business and is not guaranteed.

Frequently asked questions

Is the Humana drug I’m submitting under Part B or Part D?

For a Humana Medicare Advantage member, the channel turns on who administers the drug and where. Drugs administered by a clinician at an HOPD, infusion suite, or office (IV, IM, or in-clinic SC) are billed under the medical benefit as Part B — the practice does benefits investigation through HumanaProvider.com or Availity, submits PA against Humana’s MA Part B criteria (which mirror CMS Step Therapy for the designated MA Part B drug list), and bills buy-and-bill at ASP-based pricing with Humana’s MA wrap. Drugs self-administered at home (oral, most SC injectables) flow through the pharmacy benefit as Part D — they route through CenterWell or another in-network Part D specialty pharmacy, with tier-based copay and formulary-driven PA criteria. This Part B vs Part D fork is the single most important upfront decision on a Humana specialty PA, and it matters more for Humana than for the commercial payers because Humana’s book is roughly 80%+ Medicare Advantage.

What is CenterWell Specialty Pharmacy and how does it relate to Humana Pharmacy?

CenterWell Specialty Pharmacy is the rebranded specialty and mail-order pharmacy operated by Humana, consolidated under the CenterWell brand during the 2022-2024 rebrand of the legacy Humana Pharmacy and Humana Specialty Pharmacy operations. Humana Pharmacy Solutions (HPS) remains the broader PBM identity that administers the Humana pharmacy benefit and operates the formulary and PA criteria infrastructure; CenterWell is the dispensing arm. For Part D specialty drugs, CenterWell is the default in-network specialty pharmacy on most Humana MA-PD and stand-alone PDP plans. A small number of REMS-restricted drugs and limited-distribution oncology agents stay with manufacturer-designated specialty pharmacies.

Does CMS Step Therapy apply to Humana MA Part B drugs?

Yes. Since the 2019 CMS rule (and subsequent expansions through 2024-2026), Medicare Advantage organizations are permitted to apply step therapy to Part B drugs under defined guardrails, and Humana enforces this on the MA Part B drug list aggressively. The step-therapy criteria mirror or align with the CMS-permitted framework — typically requiring a preferred biosimilar before a reference biologic, or a lower-cost preferred Part B drug before a higher-cost alternative. Documented prior trial of the preferred agent, intolerance, or contraindication is the exception pathway. PCCs submitting MA Part B PAs on biosimilar-eligible reference products (Avastin, Remicade, Rituxan, Herceptin, Neulasta, Humira) should attach step-through documentation by default to avoid the auto-pend.

Does Humana require CED registry enrollment for Aduhelm, Leqembi, or Kisunla?

Yes. Humana follows the CMS National Coverage Determination requiring Coverage with Evidence Development (CED) for monoclonal antibodies directed against amyloid for Alzheimer’s disease — Aduhelm (aducanumab, withdrawn from the market 2024), Leqembi (lecanemab), and Kisunla (donanemab). Coverage requires the patient be enrolled in a qualifying CMS-approved registry, the prescribing clinician complete the registry data collection requirements, and the administering site meet CMS facility criteria. PAs submitted without CED registry enrollment evidence are denied. The Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET) is the most widely used CED registry; site registration and per-patient data entry are part of the workflow.

How does TRICARE coverage through Humana Military work for specialty drugs?

Humana Military administers the TRICARE East Region contract on behalf of the Defense Health Agency (the West Region is administered by a separate contractor). For TRICARE beneficiaries seen at civilian network providers, specialty drug PA and pharmacy benefits follow TRICARE-specific rules — not standard Humana MA or commercial rules. TRICARE uses Express Scripts for the TRICARE Pharmacy Program (TPharm) for mail-order and most retail specialty Rx. Buy-and-bill medical-benefit drugs at network providers follow TRICARE medical-benefit PA. Verify the TRICARE plan (Prime, Select, For Life, Reserve Select) and route to the correct portal — TRICARE workflows do not live on HumanaProvider.com.

What is Humana’s appeals process for MA specialty drug denials?

Humana MA follows the CMS-regulated MA appeals structure: Plan Reconsideration (Level 1, internal redetermination by Humana — TAT 7 calendar days for standard pre-service Part D, 72 hours expedited Part D; 30 calendar days standard pre-service Part B, 72 hours expedited Part B), then automatic forwarding to the Independent Review Entity (Level 2 — Maximus Federal Services handles Part D IRE, C2C Innovative Solutions handles Part C / Part B IRE), then ALJ hearing, Medicare Appeals Council review, and Federal Court review. TATs at each level are CMS-mandated. Adverse Part D coverage determinations also offer a separate coverage determination redetermination pathway distinct from Part B. Always confirm the level-1 deadline on the denial notice — it varies by Part B vs Part D and by standard vs expedited.

How do dual-eligible (Medicare-Medicaid) members on Humana plans pay for specialty drugs?

Dual-eligibles enrolled in a Humana D-SNP (Dual Eligible Special Needs Plan) have integrated Medicare and Medicaid coverage with simplified cost-sharing. The Low Income Subsidy (LIS, also called Extra Help) caps Part D specialty drug copays at substantially reduced levels — typical 2026 LIS copay tiers cap generic and brand at fixed dollar amounts well below standard MA-PD specialty tiers. Dual-eligibles are also categorically ineligible for manufacturer copay assistance programs (federal anti-kickback statute), so foundation grants from Patient Access Network Foundation, HealthWell Foundation, Patient Advocate Foundation Co-Pay Relief, and similar 501(c)(3) charitable foundations are the primary supplemental funding path. Verify LIS status (the four LIS levels carry different copay caps) on the patient’s plan documentation before quoting cost.

What’s different about Humana’s site-of-care policy versus UHC or Aetna?

Humana’s commercial site-of-care steerage is the least aggressive among the four major payers — in part because Humana’s commercial book is small and shrinking (Humana exited the commercial group ACA market in 2024 and continues to wind down commercial group). The dominant Humana site-of-care framework is CMS-driven for MA Part B: Humana enforces the CMS Local Coverage Determinations and National Coverage Determinations that govern site-of-care for specific Part B drugs, plus Humana-specific medical policy where CMS permits. Office-based infusion (POS 11) is generally preferred over HOPD (POS 22) on cost grounds, but Humana has not built a UHC-style Outpatient Hospital Site of Care Review program with dedicated site-of-service PA gates. Home infusion exploration is ongoing but adoption has been slower than at UHC.

Sources

• HumanaProvider.com — Prior Authorization and Notification reference documentation for Humana Medicare Advantage and commercial (legacy) lines of business, current calendar year. Accessible at humana.com/provider (provider login required for criteria documents). Paraphrased.
• CenterWell Specialty Pharmacy provider portal — Part D specialty Rx referral workflow, PA criteria summary, and clinical management resources, current calendar year. Accessible at centerwellspecialtypharmacy.com.
• Humana Medical Coverage Policies — site-of-care, biosimilar substitution, specialty drug management, MA Part B medical policy bulletins. Published on HumanaProvider.com under Medical Coverage Policies.
• CMS Medicare Advantage Step Therapy guidance — Medicare Advantage prescription drug step therapy framework documents (2019 final rule and subsequent CMS sub-regulatory guidance through 2024-2026), governing MA Part B step therapy permissibility.
• CMS National Coverage Determination 200.3 — Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease (Coverage with Evidence Development framework for Aduhelm, Leqembi, Kisunla).
• CMS Local Coverage Determinations (LCDs) relevant to MA Part B specialty drugs, current versions on the MCD database.
• Humana Pharmacy Solutions (HPS) formulary documents and Part D coverage determination forms, current quarter.
• Humana Military TRICARE East Region provider materials — TRICARE Pharmacy Program and medical-benefit PA workflows for TRICARE beneficiaries. Accessible at humanamilitary.com.
• AHIP Medicare Advantage operational guidance, current edition (cross-reference).
• BCBS Association biosimilar substitution policy framework (used as cross-reference for MA Part B biosimilar mandate norms).

All sources are publicly available payer or CMS policy documents, or paraphrased from trade-association educational materials. Payer policy URLs, fax numbers, and criteria change — and Humana’s MA-heavy book means CMS rule changes flow through to Humana operations within a quarter or two. Verify any operational detail (fax, portal URL, specific PA criteria, CED registry requirement) on HumanaProvider.com, the CenterWell provider portal, or the current CMS guidance before submission. The methodology by which we resolve source conflicts is described in the Methodology.

Related references